Jacob Schachter
Overview
Explore the profile of Jacob Schachter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
155
Citations
12160
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lens M, Schachter J
Curr Treat Options Oncol
. 2025 Jan;
26(1):36-44.
PMID: 39752093
Clinical management of melanoma brain metastases is complex and requires multidisciplinary approach. With close collaboration between neurosurgeons, radiation oncologists and medical oncologists, melanoma patients with brain are offered different treatment...
2.
Ajayi A, Schachter J, Goblirsch N, Zhou R
J Couns Psychol
. 2024 Oct;
72(1):30-44.
PMID: 39446643
The current pilot randomized controlled trial evaluated the acceptability, feasibility, and preliminary efficacy of a mental health promotion intervention for college students based on trauma-focused acceptance and commitment therapy (Harris,...
3.
Asher N, Bar-Hai N, Ben-Betzalel G, Stoff R, Grynberg S, Schachter J, et al.
Melanoma Res
. 2024 Jun;
34(5):439-449.
PMID: 38913412
Several studies have demonstrated that patients who experience immune-related adverse events (irAE) as a result of immunotherapy treatment, exhibit significantly improved outcomes compared to patients without toxicity. Data regarding the...
4.
Long G, Hauschild A, Santinami M, Kirkwood J, Atkinson V, Mandala M, et al.
N Engl J Med
. 2024 Jun;
391(18):1709-1720.
PMID: 38899716
Background: The 5-year results of this trial showed that adjuvant therapy with dabrafenib plus trametinib resulted in longer relapse-free survival and distant metastasis-free survival than placebo among patients with V600-mutated...
5.
Grynberg S, Vered M, Shapira-Frommer R, Asher N, Ben-Betzalel G, Stoff R, et al.
J Natl Cancer Inst
. 2023 Nov;
116(4):539-546.
PMID: 37966914
Background: Ameloblastoma is a rare odontogenic neoplasm frequently located in the mandible. Standard treatment involves radical bone resection and immediate reconstruction, causing functional, aesthetic, and psychological impairments. The BRAF V600E...
6.
Bratland A, Munoz-Couselo E, Mortier L, Roshdy O, Gonzalez R, Schachter J, et al.
Dermatol Ther (Heidelb)
. 2023 Nov;
13(12):3165-3180.
PMID: 37943491
Introduction: At first interim analysis of KEYNOTE-629, health-related quality of life (HRQoL) with pembrolizumab was stable or improved over 48 weeks in recurrent or metastatic (R/M) cutaneous squamous cell carcinoma...
7.
Pepys J, Stoff R, Ramon-Gonen R, Ben-Betzalel G, Grynberg S, Frommer R, et al.
Neurology
. 2023 Aug;
101(24):e2472-e2482.
PMID: 37652699
Background And Objectives: Neurologic immune-related adverse events (n-irAEs) reportedly occur in up to 8% of patients treated with immune checkpoint inhibitors (ICIs) of all age groups. We investigated the association...
8.
Robert C, Carlino M, McNeil C, Ribas A, Grob J, Schachter J, et al.
J Clin Oncol
. 2023 Jun;
41(24):3998-4003.
PMID: 37348035
JCO Immune checkpoint inhibitors have led to unprecedented prolongation of overall survival (OS) for patients with advanced melanoma. Five-year follow-up of KEYNOTE-006 showed pembrolizumab prolonged survival versus ipilimumab. Efficacy results...
9.
Mor E, Schtrechman G, Nizri E, Shimonovitz M, Asher N, Ben-Betzalel G, et al.
Eur J Surg Oncol
. 2023 Jun;
49(10):106950.
PMID: 37301639
Introduction: Modern systemic therapy has revolutionized the treatment of melanoma. Currently, patients with clinically involved lymph nodes require lymphadenectomy with associated morbidities. Positron Emission Tomography - Computed Tomography (PET-CT) has...
10.
Bar-Hai N, Ben-Betzalel G, Stoff R, Grynberg S, Schachter J, Shapira-Frommer R, et al.
Cancers (Basel)
. 2023 Jun;
15(11).
PMID: 37297003
Background: Successful treatment with Immune Checkpoint Inhibitors (ICI) requires the balanced activation of the immune system. Over-activation may result in immune-related adverse events (irAEs), which often require steroidal treatment. This...